SUBSCRIBE
SUBSCRIBE
News   Drug Development

Newron Pharmaceuticals Says Phase II Study Show Painkiller Ralfinamide Improves Quality of Life

July 17, 2007 | 
1 min read

ZURICH (Thomson Financial) - Newron Pharmaceuticals SpA said its painkiller ralfinamide improved patients’ quality of life compared to a placebo in phase II clinical tests.

Clinical research Phase II Europe
MORE ON THIS TOPIC
The EMA's former headquarters in London
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Beautiful colorful unpeeled peanut pattern on a light blue background. Flat lay arrangement, top view.
Immunology and inflammation
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Human Nose Like Worker Is Going To Work. Vector Collage Illustration Against The Background Of The City
Immunology and inflammation
AstraZeneca, Amgen’s Phase III Win Strengthens Case for Tezspire Expansion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
3D illustration of an RNA molecule
Cardiovascular disease
Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac